| Type | Public |
|---|---|
| Traded as | ZEL |
| Industry | Pharmaceuticals and Chemicals |
| Founded | August 3, 1939 |
| Founder(s) | Fernández Family |
| Headquarters | Madrid, Spain |
| Area served | Worldwide |
| Key people | José Fernández Sousa-Faro (Chairman) |
| Products | Xylazel, Zelnova, Yondelis |
| Revenue |
US$176 million (2009) |
| Operating income | (US$46.3 million) (2009) |
| Net income | (US$40.3 million) (2009) |
| Total assets | US$302.9 million (2009) |
| Total equity | US$59 million (2009) |
| Employees | 26 (not including subsidiaries) |
| Subsidiaries | PharMar, Genomica, Sylentis, Noscira |
| Website | Spanish language homepage |
| References: [finan 1][history 1] | |
Zeltia is a public company founded and headquartered in Spain which operates through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.[history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEO's have experienced to produce immediate returns.[history 3]
Contents |
Direct subsidiaries as of 2009 were:[finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.
Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were:[finan 2] Pharma Mar US; Pharma Mar AG; Pharma Mar SARL; Pharma Mar GmbH; Pharma Mar Ltd.
A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A.[finan 2]